u/Confident_Key_5228

EMBC makes the needles people with diabetes use every single day, yet Wall Street is pricing it like it's about to go out of business

Embecta, the global leader in insulin pen needles and syringes, is trading at 4x earnings after a severe May sell-off despite generating stable cash and paying down debt. The GLP-1 fear is overblown—type 1 diabetics require insulin for life, and most GLP-1 users regain weight within a year—while management executes on deleveraging and product expansion via the Owen Mumford acquisition.